HER2-Specific CAR T / Cellevolve Bio, Seattle Children’s Therapeutics - LARVOL DELTA

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Trial primary completion date: Jul 2024 ➔ Jul 2025

CAR T-Cell Therapy • IO biomarker • Trial primary completion date • Brain Cancer • CNS Tumor • Embryonal Tumor • Ependymoma • Germ Cell Tumors • Glioma • Medulloblastoma • Oncology • Pediatrics • Pineoblastoma • Rhabdoid Tumor • Sarcoma • Solid Tumor • HER-2

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Seattle Children's Hospital | Recruiting ➔ Active, not recruiting | N=48 ➔ 10

Enrollment change • Enrollment closed • Brain Cancer • CNS Tumor • Embryonal Tumor • Ependymoma • Germ Cell Tumors • Glioma • Medulloblastoma • Oncology • Pediatrics • Pineoblastoma • Rhabdoid Tumor • Sarcoma • Solid Tumor • HER-2